Skip to main content
SpringerLink
Log in
Book cover

JIMD Reports, Volume 18 pp 1–11Cite as

Growth Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux–Lamy Syndrome)

  • Research Report
  • Chapter
  • First Online:

Part of the book series: JIMD Reports ((JIMD,volume 18))

Abstract

Background: The skeletal phenotype of mucopolysaccharidosis VI (MPS VI) is characterized by short stature and growth failure.

Objective: The purpose of this study was to construct reference growth curves for MPS VI patients with rapidly and slowly progressive disease.

Methods: We pooled cross-sectional and longitudinal height for age data from galsulfase (Naglazyme®, BioMarin Pharmaceutical Inc.), treatment naïve patients (n = 269) who participated in various MPS VI studies, including galsulfase clinical trials and their extension programs, the MPS VI clinical surveillance program (CSP), and the MPS VI survey and resurvey studies, to construct growth charts for the MPS VI population. There were 229 patients included in this study, of which data from 207 patients ≤25 years of age with 513 height measurements were used for constructing reference growth curves.

Results: Height for age growth curves for the 5th, 10th, 25th, 50th, 75th, 90th, and 95th percentiles were constructed for patients with rapidly and slowly progressing disease defined by the pre-enzyme replacement therapy (ERT) uGAG levels of > or ≤200 μg/mg creatinine. The mean (SD) pre-ERT uGAG levels were 481.0 (218.6) and 97.8 (56.3) μg/mg creatinine for the patients ≤25 years of age with rapidly (n = 131) and slowly (n = 76) progressing MPS VI disease, respectively. The median growth curves for patients with ≤ and >200 μg/mg creatinine were above and below the median (50th percentile) growth curve for the entire MPS VI population.

Conclusion: MPS VI growth charts have been developed to assist in the clinical management of MPS VI patients.

Competing interests: None declared

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

CDC:

Centers for Disease Control and Prevention

CSP:

Clinical surveillance program

ERT:

Enzyme replacement therapy

GAG:

Glycosaminoglycans

HSCT:

Hematopoietic stem cell transplant

LMS:

Lambda Mu Sigma

MPS VI:

Mucopolysaccharidosis VI

uGAG:

Urinary glycosaminoglycans

References

  • Abreu S, Hayden J, Berthold P et al (1995) Growth plate pathology in feline mucopolysaccharidosis VI. Calcif Tissue Int 57(3):185–190

    Article  CAS  PubMed  Google Scholar 

  • Alliston T (2010) Chondroitin sulfate and growth factor signaling in the skeleton: possible links to MPS VI. J Pediatr Rehabil Med 3(2):129–138

    PubMed Central  PubMed  Google Scholar 

  • Borges MF, Tavares FS, Silva PCL et al (2003) Mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome): endocrine evaluation of three cases. Arq Bras Endocrinol Metab 47(1):87–94

    Article  Google Scholar 

  • Buyukgebiz B, Eroglu Y, Kovanlikaya I, Sen A, Buyukgebiz A (1995) Maroteaux–Lamy syndrome associated with growth hormone deficiency. J Pediatr Endocrinol Metab 8(4):305–307

    Article  CAS  PubMed  Google Scholar 

  • Cole TJ (1989) Using the LMS method to measure skewness in the NCHS and Dutch National height standards. Ann Hum Biol 16(5):407–419

    Article  CAS  PubMed  Google Scholar 

  • Cole TJ, Green PJ (1992) Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med 11(10):1305–1319

    Article  CAS  PubMed  Google Scholar 

  • de Ruijter J, Broere L, Mulder MF et al (2013) Growth in patients with mucopolysaccharidosis type III (Sanfilippo disease). J Inherit Metab Dis. doi:10.1007/s10545-10013-96583

    Google Scholar 

  • Decker C, Yu Z-F, Giugliani R et al (2010) Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med 3(2):89–100

    PubMed Central  PubMed  Google Scholar 

  • Furujo M, Kubo T, Kosuga M, Okuyama T (2011) Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. Mol Genet Metab 104(4):597–602

    Article  CAS  PubMed  Google Scholar 

  • Gallegos-Arreola MP, Machorro-Lazo MV, Flores-Martinez SE et al (2000) Urinary glycosaminoglycan excretion in healthy subjects and in patients with mucopolysaccharidoses. Arch Med Res 31(5):505–510

    Article  CAS  PubMed  Google Scholar 

  • Gardner CJ, Robinson N, Meadows T et al (2011) Growth, final height and endocrine sequelae in a UK population of patients with Hurler syndrome (MPS1H). J Inherit Metab Dis 34(2):489–497

    Article  PubMed  Google Scholar 

  • Giugliani R, Harmatz P, Wraith JE (2007) Management guidelines for mucopolysaccharidosis VI. Pediatrics 120(2):405–418

    Article  PubMed  Google Scholar 

  • Giugliani R, Lampe C, Guffon N et al (2014) Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy Syndrome)—10 year follow-up of patients who previously participated in an MPS VI survey study. Am J Med Genet Part A. doi:10.1002/ajmg.a.36584

    PubMed Central  Google Scholar 

  • Gray G, Claridge P, Jenkinson L, Green A (2007) Quantitation of urinary glycosaminoglycans using dimethylene blue as a screening technique for the diagnosis of mucopolysaccharidoses: an evaluation. Ann Clin Biochem 44(Pt 4):360–363

    Article  CAS  PubMed  Google Scholar 

  • Hall JG, Allanson JE, Gripp KW, Slavotinek AM (2012) Special section. Syndrome-specific growth charts. Am J Med Genet A 158A(11):2645–2646

    Article  PubMed  Google Scholar 

  • Harmatz P, Whitley C, Waber L et al (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux–Lamy syndrome). J Pediatr 144(5):574–580

    Article  CAS  PubMed  Google Scholar 

  • Harmatz P, Ketteridge D, Giugliani R et al (2005) Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux–Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115(6)

    Google Scholar 

  • Harmatz P, Giugliani R, Schwartz I et al (2006) Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 148(4):533–539

    Article  CAS  PubMed  Google Scholar 

  • Harmatz P, Giugliani R, Schwartz IV et al (2008) Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 94(4):469–475

    Article  CAS  PubMed  Google Scholar 

  • Harmatz PR, Garcia P, Guffon N et al (2013) Galsulfase (Naglazyme(R)) therapy in infants with mucopolysaccharidosis VI. J Inherit Metab Dis. doi:10.1007/s10545-013-9654-7

    Google Scholar 

  • Hendriksz C, Giugliani R, Harmatz P et al (2013) Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis 36(2):373–384

    Article  PubMed  Google Scholar 

  • Heron D, Baumann C, Benichou JJ, Harpey JP, Le Merrer M (2004) Early diagnosis of Maroteaux–Lamy syndrome in two patients with accelerated growth and advanced bone maturation. Eur J Pediatr 163(6):323–326

    Article  PubMed  Google Scholar 

  • Horovitz DD, Magalhaes TS, Acosta A et al (2013) Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI. Mol Genet Metab 109(1):62–69

    Article  CAS  PubMed  Google Scholar 

  • Horton WA, Hall JG, Scott CI, Pyeritz RE, Rimoin DL (1982) Growth curves for height for diastrophic dysplasia, spondyloepiphyseal dysplasia congenita, and pseudoachondroplasia. Am J Dis Child 136(4):316–319

    CAS  PubMed  Google Scholar 

  • Jurecka A, Zakharova E, Cimbalistiene L et al (2013) Mucopolysaccharidosis type VI in Russia, Kazakhstan, and Central and Eastern Europe. Pediatr Int. doi:10.1111/ped.12281

    Google Scholar 

  • Kantaputra PN, Kayserili H, Guven Y et al (2014) Clinical manifestations of 17 patients affected with mucopolysaccharidosis type VI and eight novel ARSB mutations. Am J Med Genet Part A 164(6):1443–1453

    Article  CAS  Google Scholar 

  • Karageorgos L, Brooks DA, Pollard A et al (2007) Mutational analysis of 105 mucopolysaccharidosis type VI patients. Hum Mutat 28(9):897–903

    Article  CAS  PubMed  Google Scholar 

  • Kuczmarski R, Ogden C, Guo S et al (2002) 2000 CDC growth charts for the United States: Methods and development. Vital Health Stat 11(246):1–190

    Google Scholar 

  • Lachman R, Martin KW, Castro S, Basto MA, Adams A, Teles EL (2010) Radiologic and neuroradiologic findings in the mucopolysaccharidoses. J Pediatr Rehabil Med 3(2):109–118

    PubMed  Google Scholar 

  • Neufeld EF, Muenzer J (2013) The mucopolysaccharidoses. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G (eds) OMMBID – the online metabolic and molecular bases of inherited diseases. McGraw-Hill, New York. http://ommbid.mhmedical.com/content.aspx?bookid=474&Sectionid=45374136. Accessed 23 Jan 2014

  • Polgreen LE, Tolar J, Plog M et al (2008) Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant 41(12):1005–1011

    Article  CAS  PubMed  Google Scholar 

  • Polgreen LE, Thomas W, Fung E et al (2014) Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VI. J Clin Densitom 17(1):200–206

    Article  PubMed Central  PubMed  Google Scholar 

  • Ranke MB (1989) Disease-specific growth charts–do we need them? Acta Paediatr Scand Suppl 356:17–25

    Article  CAS  PubMed  Google Scholar 

  • Scarpa M, Barone R, Fiumara A et al (2009) Mucopolysaccharidosis VI: the Italian experience. Eur J Pediatr 168(10):1203–1206

    Article  PubMed  Google Scholar 

  • Simonaro CM, Ge Y, Eliyahu E, He X, Jepsen KJ, Schuchman EH (2010) Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A 107(1):222–227

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Swiedler S, Beck M, Bajbouj M et al (2005) Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux–Lamy syndrome). Am J Med Genet A 134A(2):144–150

    Article  PubMed  Google Scholar 

  • Tarquinio DC, Motil KJ, Hou W et al (2010) Growth failure and outcome in Rett syndrome: specific growth references. Neurology 79(16):1653–1661

    Article  Google Scholar 

  • Tomatsu S, Montaño A, Oikawa H et al (2012) Impairment of body growth in mucopolysaccharidoses. In: Preedy V (ed) Handbook of growth and growth monitoring in health and disease. Springer, New York, pp 2091–2117

    Google Scholar 

  • Tylki-Szymanska A, Rozdzynska A, Jurecka A, Marucha J, Czartoryska B (2010) Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase). Mol Genet Metab 99(1):10–17

    Article  CAS  PubMed  Google Scholar 

  • von Muhlendahl KE, Bradac GB (1975) Empty Sella syndrome in a boy with mucopolysaccharidosis type VI (Maroteaux–Lamy). Helv Paediatr Acta 30(2):185–190

    Google Scholar 

  • White K (2011) Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford) 50(Suppl 5):26–33

    Google Scholar 

  • Whitley CB, Ridnour MD, Draper KA, Dutton CM, Neglia JP (1989) Diagnostic test for mucopolysaccharidosis. I. Direct method for quantifying excessive urinary glycosaminoglycan excretion. Clin Chem 35(3):374–379

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was performed based on the suggestion of the MPS VI CSP publication advisory board (Drs Jim McGill, Rossella Parini, Ans van der Ploeg, Paul Harmatz, Chris Hendriksz, Christina Lampe, Vassili Valayannopoulos, and Elisa Leão-Teles). The clinical trials data was provided by the MPS VI Study Group coinvestigators (see below). This study was supported by BioMarin Pharmaceutical Inc. and, in part, with funds provided by the National Institutes of Health/National Center for Research Resources (NIH/NCRR) CTSA grant UL1RR024131 (Dr Harmatz). The Authors thank Prof Tim Cole, Center for Pediatric Epidemiology and Biostatistics, UCL Institute of Child Health, London, UK, for his expert advice; Ajay K. Malik, PhD, (BioMarin) for medical writing and graphics support; and Robert Matousek (BioMarin) for statistical analysis.

The MPS VI Study Group coinvestigators were Agata Fiumara, MD, Department of Pediatrics, University of Catania, Catania, Italy; Ana Cecília Azevedo, MD, Serviço de Genética Médica/HCPA and Department of Genetics/UFRGS, Porto Alegre, Brazil; Ana Maria Martins, MD, UNIFESP, Instituto de Oncologia Pediátrica, GRAACC/UNIFESP, Departamento de Pediatria, São Paulo, Brazil; Anne O’Meara, MD, Our Lady’s Hospital for Sick Children, Dublin, Ireland; Barbara Plecko, Univ. Klinik fur Kinder und Jugendheilkunde, Graz, Austria; Prof. Billette de Villemeur, Hôpital Trousseau, Paris, France; Bonito Victor, MD, Unidade de Doenças Metabólicas, Departamento Pediatria, Hospital de Sao João, Porto, Portugal; Chester B. Whitley, University of Minnesota Medical School, Minneapolis, MN, USA; Claudia Lee, MPH, Children’s Hospital & Research Center Oakland, Oakland, California; David Ketteridge, Department of Genetic Medicine, Women’s and Children’s Hospital Adelaide, North Adelaide, Australia; David Sillence, MD, Children’s Hospital, Westmead, Australia; D.N. Bennett-Jones, MD, Consultant General & Renal Physician, Whitehaven, UK; Eduardo Coopman, MD, Hospital del Cobre De. Salvador, Calama, Chile; Elio Gizzi, MD, Children’s Hospital & Research Center Oakland, Oakland, California; Elisa Leão-Teles ,MD, Unidade de Doenças Metabólicas, Departamento Pediatria, Hospital de Sao João, Porto, Portugal; Emerson Santana Santos, MD, Fundação Universidade de Ciências da Saúde de Alagoas Governador, Departamento de Pediatria, Maceió, Brazil; Eugênia Ribeiro Valadares, MD, PhD, Hospital das Clínicas, Faculdade de Medicina da Universidade Federal de Minas Gerais-UFMG, Avenida Professor Alfredo Balena, Belo Horizonte-Minas Gerais, Brazil; Prof Giovanni Sorge, Department of Pediatrics, University of Catania, Catania, Italy; Gregory Pastores, MD, PhD, NYU Medical Center, Rusk Institute, New York, New York; Ida Vanessa D. Schwartz, MD, Serviço de Genética Médica/HCPA and Department of Genetics/UFRGS, Porto Alegre, Brazil; Isabel Cristina Neves de Souza, MD, Universidade Federal do Pará, Centro de Ciências Biológicas, Hospital Universitário João de Barros Barreto, Belém, Brazil; Javier Arroyo, MD, Hospital San Pedro de Alcantara, Hospital de día de Pediatría, Caceres, Spain; J. Edmond Wraith, MD, Royal Manchester Children’s Hospital, Manchester, UK; John J. Hopwood, Department of Genetic Medicine, Women’s and Children’s Hospital Adelaide, North Adelaide, Australia; John Waterson, MD, PhD, Children’s Hospital & Research Center Oakland, Oakland, California; Julie Simon, RN, Children’s Hospital & Research Center Oakland, Oakland, California; Laila Arash, Children’s Hospital, University of Mainz, Germany; Laura Keppen, MD, Department of Pediatrics, University of South Dakota School of Medicine, Sioux Falls, SD; Lewis Waber, MD, PhD, Pediatric Genetics and Metabolism, University of Texas Southwest Medical Center, Dallas, TX; Lionel Lubitz, MD, Royal Children’s Hospital, Melbourne, Australia; Lorenzo Pavone, MD, Department of Pediatrics, University of Catania, Catania, Italy; Luiz Carlos Santana da Silva, PhD, Universidade Federal do Pará, Centro de Ciências Biológicas, Hospital Universitário João de Barros Barreto, Belém, Brazil; Maurizio Scarpa, Department of Pediatrics, University of Padova, Padova, Italy; M. Clara Sá Miranda, MD, Unidade de Biologia do Lisossoma e Peroxisoma, Instituto de Biologia Molecular e Celular, Porto, Portugal; Michael Beck, MD,Children’s Hospital, University of Mainz, Germany; Michel Kretz, MD, Hôpital Civil de Colmar, Le Parc Centre de la Mère et de l’Enfant, Colmar, France; Nathalie Guffon, MD, Hôpital Edouard Herriot Pavillon S, Maladies Metaboliques, Lyon, France; Paige Kaplan, Children’s Hospital of Philadelphia, Philadelphia, PA, USA; Paul Harmatz, MD Children’s Hospital & Research Center Oakland, Oakland, California; Philippe Bernard, MD, Centre Hospitalier d’Arras, Arras, France; Raquel Boy, MD, Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil; Ray Pais, MD, Pediatric Hematology/Oncology, East Tennessee Children’s Hospital, Knoxville, TN; Rita Barone, MD, Department of Pediatrics, University of Catania, Catania, Italy; Robert Steiner, Departments of Pediatrics and Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA; Roberto Giugliani, MD, PhD, Serviço de Genética Médica/HCPA and Department of Genetics/UFRGS, Porto Alegre, Brazil; Prof Rudolf Korinthenberg, Universitätsklinikum Freiburg, Zentrum für Kinderheilkunde und Jugendmedizin, Klinik II Neuropädiatrie und Muskelerkrankungen, Freiburg, Germany; Shuan-Pei Lin, MD, MacKay Memorial Hospital, Department of Genetics, Taipei, Taiwan; Silvio Pozzi, MD, Ospedale Vito Fazzi, UO Pediatria, Lecce, Italy; Simon Jones, MD, Royal Manchester Children’s Hospital, Manchester, UK; Stephanie Oates, RN Department of Genetic Medicine, Women’s and Children’s Hospital Adelaide, North Adelaide, Australia; Susan Conrad, MD, Children’s Hospital & Research Center Oakland, Oakland, California; Uwe Preiss, MD, Universitaetsklinik und Poliklinik fuer Kinder, Halle, Germany; William Frischman, MD, The Townsville Hospital, Townsville, Australia; Yasmina Amraoui, MD, Children’s Hosp, University of Mainz, Germany.

Author information

Authors and Affiliations

  1. BioMarin Pharmaceutical Inc., Novato, CA, USA

    Adrian Quartel, Sue Graham & Ping Lin

  2. Manchester Academic Health Science Centre, The Mark Holland Metabolic Unit Salford Royal Foundation NHS Trust, Manchester, M6 8HD, UK

    Christian J. Hendriksz

  3. University Hospital San Gerardo, Monza, Italy

    Rossella Parini

  4. UCSF Benioff Children’s Hospital Oakland, Oakland, CA, USA

    Paul Harmatz

Authors
  1. Adrian Quartel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian J. Hendriksz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rossella Parini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sue Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ping Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paul Harmatz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Harmatz .

Editor information

Editors and Affiliations

  1. Division of Human Genetics, Medical University Innsbruck, Innsbruck, Austria

    Johannes Zschocke

  2. Division for Metabolic Diseases, University Children´s Hospital, Zürich, Switzerland

    Matthias Baumgartner

  3. Department of Pediatrics IGMD, Tulane University Medical School Hayward Genetics Center, New Orleans, Louisiana, USA

    Eva Morava

  4. Division of Child and Adolescent Neurolo, Mayo Clinic, Rochester, USA

    Marc Patterson

  5. Clinical and Molecular Genetics Unit, UCL Institute of Child Health, London, United Kingdom

    Shamima Rahman

  6. Heidelberg University Hospital Centre for Child & Adolescent Med, Heidelberg, Germany

    Verena Peters

Additional information

Communicated by: Frits Wijburg, MD, PhD

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

(PDF 1.09 MB)

(PDF 84.8 KB)

(PDF 69 KB)

(PDF 69.2 KB)

Appendices

Synopsis

Growth charts for rapidly and slowly progressing MPS VI patients.

Compliance with Ethics Guidelines

Conflict of Interest

Christian J. Hendriksz, Rossella Parini, and Paul Harmatz have worked as consultants and study investigators for BioMarin Pharmaceutical Inc., received research grants, participated in BioMarin advisory board meetings, and received speaker honoraria and travel support from BioMarin Pharmaceutical Inc. Adrian Quartel, Sue Graham, and Ping Lin are employees and stockholders of BioMarin Pharmaceutical Inc.

Patient Consent Statement

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Each participant or his/her legally authorized representative provided written informed consent before entering the study in compliance with the applicable local regulations.

Contributions of Individual Authors

Adrian Quartel contributed to the conception and research design, performed data analysis, and contributed to the writing of the manuscript.

Christian J. Hendriksz contributed to the conception and research design, acquisition of data, and revising manuscript critically for important intellectual content.

Rossella Parini contributed to the conception and research design, acquisition of data, and revising manuscript critically for important intellectual content.

Sue Graham contributed to the conception and research design and revised manuscript critically for important intellectual content.

Ping Lin contributed to the research design, developed statistical methodologies, performed statistical analyses and interpretations, and revised manuscript critically for important intellectual content.

Paul Harmatz contributed to the conception and research design and acquisition of data and contributed to the writing of the manuscript.

Guarantor: Adrian Quartel

All authors approved the final version of the manuscript and the decision to publish.

Rights and permissions

Reprints and permissions

Copyright information

© 2014 SSIEM and Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Quartel, A., Hendriksz, C.J., Parini, R., Graham, S., Lin, P., Harmatz, P. (2014). Growth Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux–Lamy Syndrome). In: Zschocke, J., Baumgartner, M., Morava, E., Patterson, M., Rahman, S., Peters, V. (eds) JIMD Reports, Volume 18. JIMD Reports, vol 18. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2014_333

Download citation

  • DOI: https://doi.org/10.1007/8904_2014_333

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-44862-5

  • Online ISBN: 978-3-662-44863-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation